Castle Biosciences, Inc.
CSTL
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test tā¦ read more
Healthcare
Diagnostics & Research
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$39.89
Price-1.77%
-$0.72
1Y
Price
Market Cap
$1.164b
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+6.3%
EBITDA Margin-0.6%
Net Profit Margin+9.4%
Free Cash Flow Margin+6.3%
EBITDA Margin-0.6%
Net Profit Margin+9.4%
Free Cash Flow MarginRevenue
$343.530m
+3.5%
1y CAGR+38.3%
3y CAGR+40.1%
5y CAGREarnings
-$12.236m
-167.1%
1y CAGR-7.0%
3y CAGR-33.9%
5y CAGREPS
-$0.45
-172.6%
1y CAGR-8.8%
3y CAGR-33.7%
5y CAGRBook Value
$467.046m
$562.786m
Assets$95.740m
Liabilities$37.139m
DebtDebt to Assets
6.6%
1.4x
Debt to EBITDAFree Cash Flow
$25.377m
-30.5%
1y CAGR+106.2%
3y CAGR+52.0%
5y CAGRNo items found.
Press Releases
Statements and updates from the company